Research ArticleComparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis
Introduction
β-Blockers have been used for hypertension treatment for decades because of their antihypertension and long-term beneficial effects on all-cause and cardiovascular mortalities.1, 2, 3 However, recent studies have found that β-blockers are less effective in reducing the incidence of stroke4 and the composite of major cardiovascular outcomes, including stroke, myocardial infarction, and death, compared with other antihypertensive drugs.5 A meta-analysis has shown that β-blockers are associated with modest reductions in cardiovascular disease, yet had no significant benefit on mortality. The study also demonstrated there was no difference between cardioselective and nonselective β-blockers in the treatment of hypertension and cardiovascular outcomes.6 Studies, however, have shown that β-blockers with moderate-to-high lipophilicity decrease mortality in coronary heart disease, all-cause mortality, and sudden cardiac death.7 The results of a recent meta-analysis demonstrated that atenolol (a hydrophilic β-blocker) was associated with an increased risk of stroke in the elderly, whereas lipophilic β-blockers, mainly metoprolol and propranolol (with moderate-to-high lipophilicity) did not increase the risk of stroke in this population.8 Furthermore, drugs with high lipophilicity may penetrate the brain and cell membrane more easily, which may help to prevent stroke and cardiac death, indicating that β-blockers with moderate-to-high lipophilicity could have a greater impact on clinical outcomes than hydrophilic β-blocker. However, there are no clinical studies or meta-analyses to directly compare the effects of lipophilic and hydrophilic β-blockers on clinical outcomes in hypertensive patients. A network meta-analysis could evaluate the comparative efficacy of different treatments that have or have not been compared directly with each other in head-to-head comparisons, provided all treatments under investigation are linked to a network of evidence. In this review, we sought to use a network meta-analysis to compare the efficacy of lipophilic β-blockers (metoprolol, propranolol, and oxprenolol) and hydrophilic β-blocker (atenolol) on clinical outcomes, including all-cause mortality, coronary heart disease, stroke, and cardiogenic mortality, in hypertensive patients.
Section snippets
Methods
This study was conducted according to the Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements.9
Network of Evidence
The literature search identified 8886 publications (2991 from MEDLINE/PubMed, 1599 from EMBASE, and 4296 from the Cochrane Database). After excluding duplicates and additional articles after review of the title or abstract, the meta-analysis included 13 hypertension studies and a total of 90,935 participants (Figure 1). The primary network of evidence is detailed in Figure 2. The characteristics of the eligible studies and the detailed results of each study are summarized in Table 1, Table 2.
Discussion
This was the first network meta-analysis to compare the lipophilic and hydrophilic β-blockers for the protective effects on all-cause mortality, stroke, cardiovascular death, and coronary heart disease. Lipophilic β-blockers were associated with less cardiovascular death than hydrophilic β-blocker. After an adjustment in baseline blood pressure, hydrophilic β-blocker was also associated with a trend to increase the risk of cardiovascular death compared with lipophilic β-blockers. Lipophilic
Conclusions
Beta-blockers play a crucial role in the management of essential hypertension. Our analysis demonstrated that compared with hydrophilic β-blocker, lipophilic β-blockers could reduce cardiovascular death and the risk of stroke. The differential effects of hydrophilic and lipophilic β-blockers may be related to their lipophilicity. Taken together, the results suggest that lipophilicity may be the important factor for the efficacy of β-blockers on clinical outcomes. Additional studies are needed
Acknowledgments
The authors thank all the staff who participated in this study.
References (40)
- et al.
Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis
Lancet
(2005) - et al.
Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis
Can J Cardiol
(2014) - et al.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Int J Surg
(2010) - et al.
Atenolol in hypertension: Is it a wise choice?
Lancet
(2004) - et al.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
Lancet
(2002) - et al.
Beta-blockers or diuretics in hypertension? A six year follow-up of blood pressure and metabolic side effects
Lancet
(1981) - et al.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Lancet
(2005) The end of beta blockers for uncomplicated hypertension?
Lancet
(2005)- et al.
The effectiveness of metoprolol versus atenolol on prevention of all-cause and cardiovascular mortality in a large Chinese population: a cohort study
Int J Cardiol
(2014) The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Arch Intern Med
(1997)
Randomised, double blind, multicenter comparison of hydrochlorothiazide, atenolol, nifedipine and enalapril in antihypertensive treatment: results of the HANE study
BMJ
British Hypertension Society Guidelines for hypertension management 1999; Summary
BMJ
Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis
CMAJ
Beta-blockers for hypertension
Cochrane Database Syst Rev
The impact of lipophilicity in drug research: a case report on β-blockers
MiniRev Med Chem
β-Blockers as initial therapy for hypertension
JAMA
First-line drugs for hypertension
Cochrane Database Syst Rev
Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study
Hypertension
African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial
JAMA
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party
Br Med J (Clin Res Ed)
Cited by (15)
Optical control of the β<inf>2</inf>-adrenergic receptor with opto-prop-2: A cis-active azobenzene analog of propranolol
2022, iScienceCitation Excerpt :Propranolol is a hall-mark beta-blocker, that effectively antagonizes both β1-AR and β2-AR at nanomolar concentrations (Baker, 2005). Moreover, the drug is effectively used to treat cardiovascular diseases (Freemantle et al., 1999; Zhang et al., 2017). Also, beta blockers such as propranolol are used to treat infantile hemangiomas (Al-Haddad et al., 2019; Hagen et al., 2018), although data on observed side effects are questioning the route of administration and advocating locally acting drugs.
β-blockers: Their new life from hypertension to cancer and migraine
2020, Pharmacological ResearchCitation Excerpt :Migraine is predominantly a neurogenic rather than a vascular disorder and β-blockers like metoprolol and propranolol appear to be efficacious because they cross the BBB, exploiting their lipid solubility and modify neuronal excitability via [56,57] (Table 3). β-1 receptor antagonism seems to modulate cortical information processing expressed as changes in visual evoked potentials (VEP) mediated through adrenaline and noradrenaline, contingent negative variation (CNV), and auditory evoked potentials (AEP), which are typically abnormal in patients with migraine [58]. Indeed, in patients treated with β-blockers, the VEP amplitude tends to normalize [59,60].
KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
2019, American Journal of Kidney DiseasesCitation Excerpt :Recommended first-line agents for BP reduction include thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers (CCBs) due to their association with consistent reductions in CVD risk.6 β-Blockers are not included in this list because these drugs are now considered significantly less effective for CVD prevention78 and stroke protection than diuretics or CCBs in the absence of ischemic heart disease or HF.79 The KDIGO work group disagreed with the statement in the ACC/AHA guideline noting that thiazide diuretics should not be used in advanced CKD due to lack of efficacy.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2018, Journal of the American College of CardiologyEffect of Propranolol on Motor Cortex Excitability in Essential Tremor: An Exploratory Study
2024, Tremor and Other Hyperkinetic MovementsLack of Effects of Renin-Angiotensin-Aldosterone System Activity and Beta-Adrenoceptor Pathway Polymorphisms on the Response to Bisoprolol in Hypertension
2022, Frontiers in Cardiovascular Medicine
Yuqing Zhang and Ningling Sun are co-first authors.
Conflict of interest: This work was supported by AstraZeneca (China).
Grant Support: This meta-analysis was supported by AstraZeneca.